ATOSSA THERAPEUTICS, INC. ATOS
We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions. Our lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM)/ selective estrogen receptor degrader (SERM/D) currently in Phase 2 clinical development. The Company is evaluating potential indications for (Z)-endoxifen based on its pharmacologic profile, including its potential for both reducing the risk of and for the treatment of breast cancer, as well as in other therapeutic areas.
We have been granted U.S. and international patents covering our proprietary (Z)-endoxifen, and we have numerous applications pending in the U.S. and in other major countries. We expect to have patent protection covering our proprietary (Z)-endoxifen through at least November 17, 2038.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $21.2M | $14.1M | $17.3M | $15.1M | $9.2M | $6.6M | $6.6M | $4.2M | $2.3M | $770.4K |
| SG&A | $16.0M | $13.5M | $14.0M | $12.6M | $11.3M | $8.0M | $10.6M | $7.2M | $4.9M | $6.5M |
| Total operating expenses | $37.1M | $27.6M | $31.4M | $27.7M | $20.5M | $14.6M | $17.3M | $11.4M | $7.6M | $8.0M |
| Operating income | -$37.1M | -$27.6M | -$31.4M | -$27.7M | -$20.5M | -$14.6M | -$17.3M | -$11.4M | -$7.6M | -$8.0M |
| Pre-tax income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M | -$17.8M | -$17.2M | -$11.4M | -$8.1M | -$6.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$34.8M | -$25.5M | -$30.1M | -$27.0M | -$20.6M | -$17.8M | -$17.2M | -$11.4M | -$8.1M | -$6.4M |
| EPS, basic | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 | — | — | — | — | — |
| EPS, diluted | -4.04 | -3.04 | -0.24 | -0.21 | -0.18 | -1.97 | -2.03 | -5.50 | -10.97 | -2.16 |
| Shares, diluted (wtd. avg.) | 8.6M | 8.4M | 126.1M | 126.6M | 117.0M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $41.3M | $71.1M | $88.5M | $110.9M | $136.4M | $39.6M | $12.6M | $10.4M | $7.2M | $3.0M |
| Total current assets | $45.6M | $74.5M | $92.2M | $118.2M | $141.2M | $42.8M | $14.3M | $11.5M | $7.9M | $3.3M |
| Property, plant and equipment | — | — | — | — | $20.0K | $21.0K | $34.4K | $54.5K | $11.5K | $55.1K |
| Other intangibles | — | — | — | — | $54.0K | $41.0K | $173.5K | $192.0K | $234.0K | $640.4K |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M | $42.8M | $14.5M | $11.7M | $8.2M | $4.1M |
| Accounts payable | $4.3M | $679.0K | $806.0K | $3.0M | $1.7M | $1.6M | $293.2K | $353.3K | $334.9K | $254.3K |
| Total current liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M | $15.7M | $1.3M | $2.9M | $1.2M | $1.0M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M | $15.7M | $1.3M | $2.9M | — | $1.0M |
| Retained earnings | -$246.6M | -$211.8M | -$186.3M | -$156.2M | -$129.2M | -$111.9M | -$94.1M | -$76.8M | -$65.4M | -$57.3M |
| Total equity | $39.4M | $71.5M | $91.0M | $118.0M | $138.1M | $27.2M | $13.2M | $8.8M | $6.9M | $3.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.8M | -$21.0M | -$20.9M | -$20.8M | -$16.5M | -$11.6M | -$9.1M | -$9.0M | -$6.6M | -$5.4M |
| Depreciation and amortisation | $16.0K | $17.0K | $23.0K | $8.0K | $23.0K | $47.0K | $52.8K | $44.2K | $129.0K | $303.5K |
| Stock-based compensation | $2.6M | $2.3M | $4.6M | $6.8M | — | — | — | — | — | — |
| Capital expenditure | $23.0K | $19.0K | $14.0K | $27.0K | $9.0K | $9.0K | $7.6K | $110.9K | — | — |
| Investing cash flow | -$23.0K | -$19.0K | -$14.0K | -$4.7M | -$9.0K | -$9.0K | -$7.6K | -$110.9K | — | -$9.2K |
| Financing cash flow | $0 | $3.7M | -$1.5M | $0 | $113.3M | $38.6M | $11.3M | $12.3M | $10.8M | $4.7M |
| Buybacks | — | $0 | $1.5M | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-124396.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$6.4M | -$8.1M | -$11.4M | -$17.2M | -$17.8M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |